MED12 and leiomyoma: On the other hand, Priya et al. reported that gain-of-function mutations in MED12 lead to fibrosis and ECM deposition in leiomyomas 44, and Ayman et al. reported that silencing MED12 reduces the expression of fibrosis-associated proteins 45; these studies suggest that increased activity or expression of MED12 may lead to organ fibrosis, similar to our observations in animal models.